DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-076/S-024

Novartis Consumer Health, Inc.
Attention: Vincent DeStefano
Associate Director, Regulatory Affairs
200 Kimble Drive
Parsippany, NJ 07054-0622

Dear Mr. DeStefano:

Please refer to your supplemental new drug application submitted August 5, 2003, received August 6, 2003, under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Habitrol® (nicotine transdermal system).

We also refer to your amendment dated February 5, 2004.

This supplemental application provides for minor changes to the carton label principal display panel and carton back panel for the 21mg (Step 1) patch.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (carton label submitted on February 5, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-076/S-024." Approval of this submission by FDA is not required before the labeling is used.

(b)(4)---------- ----------
---------- ----------
-

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, Laura Shay, Regulatory Project Manager, at (301) 827-2274.

Sincerely,

{See appended electronic signature page}

Charles Ganley, M.D.
Director
Division of Over-the-Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Charles Ganley
2/6/04 12:27:46 PM